CSL, Alentis Sign Global Deal to Develop Lixudebart
CSL and Alentis enters an exclusive global collaboration to advance lixudebart across kidney and liver diseases.
Exclusive Global Collaboration | 06/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy